July 04, 2026 a 12:38 pm

BSX: Analysts Ratings - Boston Scientific Corporation

Historical Stock Grades

As of July 2026, Boston Scientific (BSX) shows a robust distribution of analyst ratings with a strong leaning towards positive sentiment. The latest data indicates 7 Strong Buy, 19 Buy, 4 Hold, and no Sell or Strong Sell recommendations. This reflects analysts' confidence in the company's strategic direction and market leadership.

Rating	Count	Score
Strong Buy	7
Buy	19
Hold	4
Sell	0
Strong Sell	0

Sentiment Development

Over recent months, the overall sentiment towards Boston Scientific has demonstrated stability with minor fluctuations. The Strong Buy recommendations have seen a slight decrease, while Buy ratings have remained relatively consistent. Notably, Hold ratings experienced a minimal increase in recent months, highlighting some moderation in sentiment without significant negative shifts.

• The total number of ratings has shown a slight decline, driven by a reduction in Strong Buy and Buy recommendations.
• Hold ratings have observed a marginal increase, reflecting a cautious optimism among some analysts.
• There have been no Sell or Strong Sell ratings for an extended period, underscoring sustained confidence in BSX's prospects.

Percentage Trends

The distribution of ratings among analysts reveals a slight rebalancing from Strong Buy to Buy and Hold categories. In July 2026, 22% of recommendations were Strong Buys, 61% Buys, and 13% Holds. This marks an observable yet modest shift towards a more conservative stance compared to earlier months.

• Percentage of Strong Buy ratings decreased from 28% to 22% over the year, indicating tempered enthusiasm.
• Buy ratings remained a dominant category, consistently above 60% throughout the period.
• Hold ratings exhibited a slow increment, suggesting a growing cautious sentiment among analysts.

Latest Analyst Recommendations

Recent analyst recommendations for Boston Scientific show a high level of consistency in ratings. Predominantly, analysts have chosen to maintain their Buy ratings, signaling steady belief in the company's strategic approach and market position.

Date	New Recommendation	Last Recommendation	Publisher
2026-06-25	Buy	Buy	Stifel
2026-06-24	Buy	Buy	Jefferies
2026-06-16	Buy	Buy	BTIG
2026-06-04	Buy	Buy	Truist Securities
2026-06-03	Buy	Buy	BTIG

Analyst Recommendations with Change of Opinion

Several analysts have adjusted their ratings for Boston Scientific, suggesting some re-evaluation of the company's prospects. While the majority of corrections are downgrades, there are instances of upgrades indicating mixed but cautious sentiment.

Date	New Recommendation	Last Recommendation	Publisher
2026-05-29	Peer Perform	Outperform	Wolfe Research
2026-05-28	Equal Weight	Overweight	Wells Fargo
2026-03-30	Outperform	Strong Buy	Raymond James
2025-09-08	Outperform	Perform	Oppenheimer
2025-04-16	Buy	Hold	Needham

Interpretation

The consistency in positive ratings suggests a generally stable sentiment towards Boston Scientific, with analysts showing confidence in its market position and strategic initiatives. However, the recent downgrades indicate a slight caution, reflecting economic or sectoral uncertainties. The mix of opinions suggests investors may perceive both potential growth opportunities and underlying risks.

Conclusion

Boston Scientific continues to be viewed favorably by analysts, albeit with some caution as indicated by recent adjustments in ratings. Despite downgrades, the absence of Sell ratings underscores confidence in its resilient business model. As BSX expands its innovative medical solutions, it remains attractive to investors focused on long-term growth. Monitoring future sentiment changes could be crucial for prospective stakeholders to manage investment risks effectively.